{"product_id":"oregon-health-science-8th-annual-ms-and-cns-neuroimmunology-symposium-2025","title":"Oregon Health \u0026 Science 8th Annual MS and CNS Neuroimmunology Symposium 2025","description":"\u003cul\u003e\n  \u003cli\u003eTarget Audience: neurologists, neuroimmunologists, rheumatologists, ophthalmologists, neurosurgeons, physicians\u003c\/li\u003e\n  \u003cli\u003eSample video: contact me for sample video\u003c\/li\u003e\n  \u003cli\u003eInformation:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eOctober 11, 2025\u003c\/p\u003e\n\u003cp\u003eVirtual symposium\u003c\/p\u003e\n\u003cp\u003eThis accredited half-day symposium provides health care professionals information to identify, refer, treat and\/or implement practice changes to improve the care of patients with neuroimmunological disorders. Specific disorders discussed this year include a 2 part update on Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy, stopping therapy in MS, Transverse myelitis, Anti-Amyloid Therapies, and managing fatigue.\u003c\/p\u003e\n\u003cp\u003eWho should attend\u003c\/p\u003e\n\u003cp\u003eNeurologists, neuroimmunologists, rheumatologists, ophthalmologists, neurosurgeons, physicians, nurse practitioners, rehabilitation including physical and occupational therapists, researchers, and other medical professionals in the field of neuroimmunological disorders are invited to attend.\u003c\/p\u003e\n\u003cp\u003eLearning objectives\u003c\/p\u003e\n\u003cp\u003eIdentify current diagnostic criteria and treatment updates for myasthenia gravis\u003c\/p\u003e\n\u003cp\u003eRecognize clinical features and apply updated management strategies for chronic inflammatory demyelinating polyneuropathy (CIDP)\u003c\/p\u003e\n\u003cp\u003eEvaluate appropriate criteria and timing for discontinuing disease-modifying therapies in multiple sclerosis patients\u003c\/p\u003e\n\u003cp\u003eAnalyze case-based presentations of transverse myelitis to improve diagnostic accuracy and treatment decision-making\u003c\/p\u003e\n\u003cp\u003eImplement evidence-based strategies for managing fatigue in patients with multiple sclerosis\u003c\/p\u003e\n\u003cp\u003eAssess patient eligibility and monitoring requirements for anti-amyloid therapies in early-stage Alzheimer’s disease\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eTopics:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e01 Neuromuscular Part I Myasthenia Gravis – Updates\u003c\/p\u003e\n\u003cp\u003e02 Neuromuscular Part II Chronic Inflammatory Demyelinating Polyneuropathy – Updates\u003c\/p\u003e\n\u003cp\u003e03 When to stop therapy, discontinuing DMT in MS\u003c\/p\u003e\n\u003cp\u003e04 Transverse myelitis, a case-based discussion\u003c\/p\u003e\n\u003cp\u003e05 Managing Fatigue in MS\u003c\/p\u003e\n\u003cp\u003e06 Anti-Amyloid Therapies for the Treatment of Early-Stage Alzheimer’s disease\u003c\/p\u003e","brand":"Medicalcoursespro","offers":[{"title":"Default Title","offer_id":46405803344068,"sku":null,"price":13.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/7644\/4100\/files\/Oregon-Health-Science-8th-Annual-MS-and-CNS-Neuroimmunology-Symposium-2025.jpg?v=1784216412","url":"https:\/\/medicalcoursespro.com\/products\/oregon-health-science-8th-annual-ms-and-cns-neuroimmunology-symposium-2025","provider":"Medicalcoursespro","version":"1.0","type":"link"}